focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
3p on the ask. Exciting times
Its good news nonetheless. GL said they had 'one shot at goal' at this so this news is proof they haven't shanked said shot over the bar. Feb 13, 2019 circled in calendar now.
coverage in The Times today. 'New abtibiotic catches the eye. A trade of 11m shares yesterday In a London listed antibiotoc developer seeking to tap into the demand for treatments for drug-resistant superbugs caught the attention of dealers. The overhang in shares is expected to lead to a rise in the share price as supply is taken up....'
'Elena, nip up to HR and get a new ink pad for the stamp. Elena! Elena, where the hell is she?' 'She's gone to visit her sickly aunt in Cluj for two weeks, boss. Last legs, apparently' 'Ah screw it, these can wait til she gets back'
Perhaps a little disingenuous ig to have a pop at folk looking at the daily moves, given your John Motson-esque commentaries of the past. What do you make of major firms like Novartis leaving the ab space because it isn't profitable for them? It made requestion by investment, never a bad thing, though I still hold. My hope is that mtfb is taken out by one of the few remaining majors still interested in development or by one one threatened with a fine (probably paltry) for not developing abs, as considered by Lord Jim O'Neill a few days ago. From the FT: 'He said on Tuesday that the industry’s continued inactivity meant that the time had come to introduce a levy on sales of other drugs to fund market entry rewards worth up to $1.2bn for effective new antibiotics.'
That £59k sale at 29.6 seems to have done the damage. What's Amp's timeline again? Didn't they kick their debt down the road?
Graham Lumsden quoted in this piece on Novartis bailing out of the AB market. Interesting read.
https://www.bloomberg.com/news/articles/2018-07-13/superbugs-win-another-round-as-big-pharma-leaves-antibiotics
The departure of some big drugmakers such as Novartis “hopefully is going to add pressure to find ways to correct some market failings,” said Graham Lumsden, CEO of Motif Bio Plc, whose experimental antibiotic Iclaprim is under regulatory review in the U.S. “This is where the biotechs have to pick up the slack.”
Based only on two trades though, presume one buy and one sell and a wide spread. Volume almost non-existant. Listing on Nasdaq caused more hassle than it has so far been worth.
'To a US institutional investor'. Good news I think, amphion below 10% now